Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $59.63
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 9, 26 | UBS | upgrade | Neutral | Buy |
| Oct 6, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Aug 24, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Jul 31, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Jul 10, 26 | JP Morgan | upgrade | Underweight | Neutral |
| Jul 9, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| May 1, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Apr 16, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Mar 9, 26 | JP Morgan | downgrade | Overweight | Underweight |
1255 daily bars · split adjusted
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 30.45 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 23.74 | Oscillator | Neutral |
| Williams %R (14) | -87.78 | Oscillator | Buy |
| MACD (12, 26, 9) | -2.48 (Hist -0.07) | Oscillator | Strong Sell |
| Average Directional Index (14) | 30.05 (+DI 15.9 / -DI 42.7) | Trend | Strong Sell |
FY2025 · 10-K disclosure
Stock news · updated daily
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth res
Luxembourg, 21 October 2026, 13:00 CET With reference to Article 19(3) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation), ArcelorMittal announces a notification of share transactions by Lumen Investments S.à r.l., an entity forming part of the Significant Shareholder structure, is available in the Luxembourg Stock Exchange's electronic database OAM on www.bourse.lu and on ArcelorMittal's website www.arcelormittal.com under Investors > Share Transactions by Management: https://corporate.arcelormittal.com/investors/corporate-governance/share-transactions-by-management.
TTM vs. 5-year historical average (annual ratios)
| Metric | MT | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 25.0x | 11.1x · sector 16.6x | Elevated |
| Forward P/E (FY26E) | 16.5x | EPS est. 3.61 | Discount |
| Price / Book | 0.8x | 0.5x | Elevated |
| Price / Sales | 0.7x | 0.4x | Elevated |
| EV / EBITDA | 7.4x | 3.9x | Elevated |
| Return on equity | 3.3% | — | Weak |
| Gross margin | 9.6% | 13.9% | Below hist. |
| Debt / Equity | 0.26 | 0.21 | Conservative |
| Piotroski / Altman Z | 6/9 | Z 2.25 | Grey zone |
Discounted cash flow model
| EMA 20 | 64.24 | MA | Strong Sell |
| SMA 20 | 63.80 | MA | Strong Sell |
| EMA 50 | 67.21 | MA | Strong Sell |
| SMA 50 | 69.84 | MA | Strong Sell |
| SMA 200 | 63.39 | MA | Strong Sell |
FY2025 · 10-K disclosure
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | 1.18 | 0.89 | Miss -24.6% | $16.76B |
| Apr 30, 2026 | 0.72 | 0.75 | Beat 4.2% | $15.46B |
| Feb 5, 2026 | 0.56 | 0.86 | Beat 53.6% | $14.97B |
| Nov 6, 2025 | 0.58 | 0.62 | Beat 6.9% | $15.66B |
| Jul 31, 2025 | 1.33 | 1.32 | Miss -0.8% | $15.93B |
| Apr 30, 2025 | 0.71 | 1.04 | Beat 46.5% | $14.80B |
| 6-K | Aug 3, 2026 | 2026-08-03 11:50:14 | View |
| 6-K | Jul 31, 2026 | 2026-07-31 13:32:06 | View |
| 6-K | Jul 30, 2026 | 2026-07-30 12:15:39 | View |
| 6-K | Jul 24, 2026 | 2026-07-24 11:30:58 | View |
| 6-K | Jul 6, 2026 | 2026-07-06 11:10:53 | View |
| SD | Jul 1, 2026 | 2026-07-01 10:03:59 | View |
Proxy statement (DEF 14A) disclosures